News | Robotic Systems | January 21, 2020

First Robotic Coronary Angioplasties Performed With Robocath System in Germany

First robotic PCIs performed at Rheinland Klinikum Neuss Lukaskrankenhaus

Professor Michael Haude, director of Medical Clinic I at Rheinland Klinikum Neuss Lukaskrankenhaus, performing a PCI using the Robocath R-One robotic catheter guidance system. 

Professor Michael Haude, director of Medical Clinic I at Rheinland Klinikum Neuss Lukaskrankenhaus, performing a PCI using the Robocath R-One robotic catheter guidance system. 

January 21, 2020 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announced it has successfully completed its first robotic coronary angioplasties with its R-One robotic catheter guidance system in Germany. The Percutaneous coronary interventions (PCI) were performed by Professor Michael Haude, director of Medical Clinic I at Rheinland Klinikum Neuss Lukaskrankenhaus, and his team.

“I’m proud to be the first user of this brand new European robotic solution for PCI in Germany," Haude said. "These robotic interventions pave the way for a new era in interventional cardiology. The benefits brought by R-One are huge for practitioners and will drastically improve our working conditions, which will consequently benefit patient care. My team and I look forward to integrating this robotic-assisted platform for PCI into our day-to-day clinical practice.”

"Professor Haude has over 30 years experience in interventional cardiology and we rely on capitalizing on this kind of experience to develop clinical evidence and demonstrate all the benefits of our solution," said Philippe Bencteux, chairman and founder of Robocath.

These first procedures in Germany are an important strategic step, said Lucien Goffart, CEO of Robocath. He said interest from major industry players is a clear indicator of this, such as the recent purchased of Corindus by Siemens in 2019.
Founded in 2009 by Philippe Bencteux, M.D., Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. Its solutions aim to make medical procedures safer with reliable technologies, while complementing manual interventions.

R-One is the first solution developed by Robocath. It is designed to operate with precision and perform specific movements, creating better interventional conditions. It uses an open architectureto make it compatible with market-leading devices and cath labs. 

The system received European CE mark in February 2019 and started its clinical use in September 2019.

The company hopes to develop a remote treatment system for vascular emergencies.

Watch the VIDEO: First Robotic PCI Case in Germany With Robocath R-One System

For more information: www.robocath.com

 

Related Cath Lab Robot Content:

Siemens Completes Acquisition of Cath Lab Robotics Vendor Corindus

Robocath Successfully Carries Out First Robotic Coronary Angioplasties in Humans

Robocath Receives $1.5 Million in Capital for Advancement of R-One Robotic System 
 

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...